KINDSTAR GLOBAL (09960) announced its interim results for the six months ended June 30, 2025, reporting revenue of 457 million yuan (RMB), gross profit of 197 million yuan, and R&D costs of 46.046 million yuan.

According to the announcement, in the first half of 2025, the hematology testing services maintained steady growth in overall partner hospitals, adding over 90 new hospital clients. The Group's pediatric hematology segment continued to establish deep roots in specialized pediatric hematology and oncology hospitals and pediatric hematology departments of major tertiary hospitals, adding 48 new partner hospitals during the first half of 2025.

The NGS testing IG/TCR rearrangement technology products under the Group achieved sales growth of over 50% during the reporting period, demonstrating core technological advantages and product characteristics. In the neurology field, while the Group's testing projects already cover almost all neurological diseases, it continues to cultivate market demand. In the first half of the year, 34 new testing projects were added, along with 44 new partner hospitals for sample submission, further deepening cooperation projects with Nanfang Hospital.

Regarding pharmaceutical company partnerships, the neurology business line has integrated proprietary specialized testing projects into multi-center studies, strategically positioning for the future blood testing opportunities in neurodegenerative diseases.

Adhering to innovation-driven development remains fundamental to the Group's industry positioning. In the first half of 2025, the Group's research departments published 33 articles, filed 67 patent applications with 29 granted, and obtained 24 copyrights. During the reporting period, the Group added a total of 56 new R&D testing projects, including 16 molecular biology testing technology-related projects, 16 flow cytometry testing technology-related projects, 7 cytogenetic testing technology-related projects, and 6 pathology testing technology-related projects.

In the first half of 2025, the Group's core products in immune repertoire, particularly the LymTRACK business applied to minimal residual disease detection in hematological malignancies, further expanded coverage to over 160 institutions across 26 provinces, with revenue growing nearly 30% compared to the same period in 2024.

In 2024, Kindstar Beta, a subsidiary of KINDSTAR GLOBAL, achieved a perfect score in the EuroClonality EQA program for its Ig/TCR project, becoming the only laboratory in China to participate and achieve a perfect score, marking a crucial step toward internationalization in China's immune repertoire testing field.